Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) EBIAT: 2017-2019

Historic EBIAT for Monopar Therapeutics (MNPR) over the last 3 years, with Dec 2019 value amounting to -$1.2 million.

  • Monopar Therapeutics' EBIAT fell 35.53% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.2 million, marking a year-over-year decrease of 38.65%. This contributed to the annual value of -$4.2 million for FY2019, which is 30.88% down from last year.
  • As of Q4 2019, Monopar Therapeutics' EBIAT stood at -$1.2 million, which was down 63.96% from -$736,080 recorded in Q3 2019.
  • Monopar Therapeutics' EBIAT's 5-year high stood at -$372,915 during Q1 2017, with a 5-year trough of -$14.9 million in Q3 2017.
  • Its 3-year average for EBIAT is -$2.0 million, with a median of -$806,214 in 2018.
  • Data for Monopar Therapeutics' EBIAT shows a peak YoY increase of 95.70% (in 2018) and a maximum YoY decrease of 135.00% (in 2018) over the last 5 years.
  • Quarterly analysis of 3 years shows Monopar Therapeutics' EBIAT stood at -$713,583 in 2017, then declined by 24.79% to -$890,461 in 2018, then crashed by 35.53% to -$1.2 million in 2019.
  • Its EBIAT was -$1.2 million in Q4 2019, compared to -$736,080 in Q3 2019 and -$905,700 in Q2 2019.